Skip to content

Eliglustat

Glucosylceramide Synthase Inhibitor — ALIMENTARY TRACT AND METABOLISM

Also known as: cerdelga, eliglustat tartrate, Genz-112638, Genz-99067

OfpEMA approvedFDA approvedATC A16AX10

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Eliglustat is an ofp drug in the Glucosylceramide Synthase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2014. Its mechanism of action is classified as Cytochrome P450 2D6 Inhibitors, Glucosylceramide Synthase Inhibitors and P-Glycoprotein Inhibitors. DrugCentral lists 1 molecular target, including UGCG. Recorded indications include Glucosylceramide beta-glucosidase deficiency.

  • Approval status: ofp (first approved 2014 by the FDA).
  • Drug class: Glucosylceramide Synthase Inhibitor.
  • Mechanism of action: Cytochrome P450 2D6 Inhibitors; Glucosylceramide Synthase Inhibitors; P-Glycoprotein Inhibitors.
  • Molecular targets: UGCG (1 listed in DrugCentral).
  • Indications: Glucosylceramide beta-glucosidase deficiency.
  • ATC code: A16AX10 (Various alimentary tract and metabolism products).
  • Molecular formula: C23H36N2O4; molecular weight 404.55 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Glucosylceramide beta-glucosidase deficiency

Mechanism & targets

Mechanism of action (MoA)Cytochrome P450 2D6 Inhibitors; Glucosylceramide Synthase Inhibitors; P-Glycoprotein Inhibitors
Established pharmacologic classGlucosylceramide Synthase Inhibitor

Molecular targets (1)

TargetGeneActionActivity
Ceramide glucosyltransferaseUGCGinhibitorIC50 6.83

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2014-11-20EMA—Genzyme Europe BV
2014-08-19FDA—GENZYME CORP

ATC classification

ATC codeTherapeutic hierarchy
A16AX10ALIMENTARY TRACT AND METABOLISM › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › Various alimentary tract and metabolism products

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • EMA label: CYP2D6 · Testing Required
  • FDA label: CYP2D6 · Testing Required
  • HCSC label: CYP2D6 · Testing Required
  • PMDA label: CYP2D6 · Testing Required

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Product dose omission in error514.5
Weight increased271.7
Weight decreased187.9
Product dose omission issue75.3
Chitotriosidase increased66.0
Intentional dose omission57.2
Bone pain50.9
Dyspepsia50.0
COVID-1939.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Eliglustat is on its molecule page.

Molecular formulaC23H36N2O4
Molecular weight404.55 g/mol
CAS number491833-29-5
InChIKeyFJZZPCZKBUKGGU-AUSIDOKSSA-N
PubChem CID23652731
CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1=CC=C2OCCOC2=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Eliglustat used for?

DrugCentral lists the following indications for Eliglustat: Glucosylceramide beta-glucosidase deficiency.

How does Eliglustat work?

Eliglustat is classified as Cytochrome P450 2D6 Inhibitors, Glucosylceramide Synthase Inhibitors and P-Glycoprotein Inhibitors; its molecular targets in DrugCentral include UGCG (inhibitor).

When was Eliglustat first approved?

Eliglustat was first approved by the FDA in 2014.

What drug class does Eliglustat belong to?

Eliglustat is in the Glucosylceramide Synthase Inhibitor class.

What is the chemical formula of Eliglustat?

Eliglustat has the molecular formula C23H36N2O4 and a molecular weight of 404.55 g/mol.

Browse: all drugs starting with E · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval2014-08-19
AgencyFDA
Targets1
Indications1
FormulaC23H36N2O4
DrugCentral ID4834
Interactive profile